ERBB2 and cancer: Hans-Heinrich Oberg (Daniela Wesch, Kiel, Germany) showed data on the use of a tribody directed against the HER2 antigen on cancers of epidermal origin and the CD16 antigen on γδ T cells and NK cells [(HER2)xCD16].